Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).

Therapie - 1 Apr 2017

Lamoureux Fabien, Duflot Thomas

Abstract excerpt

The use of genomic markers to predict drug response and effectiveness has the potential to improve healthcare by increasing drug efficacy and minimizing adverse effects. Polymorphisms associated with inter-individual variability in drug metabolism, transport, or pharmacodynamics of major cardiovascular drugs have been identified. These include single nucleotide polymorphisms (SNP) affecting clinical outcomes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Liver-Specific Organic Anion Transporter 1

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 28237404
DOI: 10.1016/j.therap.2016.09.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).PMID 28237404Read ↗

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Semantic proximity Read ↗

[Cardiovascular pharmacogenomics].Semantic proximity Read ↗

The Role of Pharmacogenetics in Antithrombotic Therapy Management: New Achievements and Barriers Yet to OvercomeSemantic proximity Read ↗

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Semantic proximity Read ↗

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.Semantic proximity Read ↗

Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.Semantic proximity Read ↗

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read ↗

Use of genetic data to guide therapy in arterial disease.Semantic proximity Read ↗

Expanding Role of Pharmacogenomics in the Management of Cardiovascular DisordersSemantic proximity Read ↗

Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Semantic proximity Read ↗

[Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases].Semantic proximity Read ↗

Cardiovascular pharmacogenomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.